Blood clot risk much higher from Covid-19 than after vaccination: Study
The risk of developing adverse events such
as blood clots is considerably higher after infection with the SARS-CoV-2 virus than after
immunisation with Pfizer and AstraZeneca COVID-19
vaccines, according to a large UK study published in the British
Medical Journal (BMJ) on Friday.
The team led by researchers at the
University of Oxford in the UK conducted the study on thrombocytopenia -- a
condition with low platelet counts -- and thromboembolic events or blood clots
following COVID-19 vaccination with Oxford-AstraZeneca and Pfizer-BioNTech
preventives.
Some of these events have led to
restricted use of the Oxford-AstraZeneca vaccine, known as Covishield in India,
in a number of countries.
The researchers compared rates of adverse
events after vaccination with rates of the same events after a positive
SARS-CoV-2 test result using data from over 29 million people in the UK who
received the first dose of either of the two vaccines. Read
More
Comments
Post a Comment